Dear Dianne and Group, Almost two years ago I had episodes of heart failure, but last years a was retested and I showed no signs of it. I am thinking it was the Gleevec...possibly congestion from the drug. I am happy that I have "out-grown it".
Dee Hedman diagnosed July 2002 --- anjana <[EMAIL PROTECTED]> wrote: > > Dear Dianne, > > Gleevec is not so much associated with heart > problems. The sites > below list low and high blood pressure as rare > side-effects of Gleevec > and tachycardia which is rapid heart rhythm. > There are some examples > of fluid in the pericardial sac from Gleevec > fluid retention. But I > did not come across anything with heart valve > problems and Gleevec. > There was an article of one case of cardiac > tamponade from the fluid > around the heart. And below is the most recent > one from Korea. I > searched Pubmed. > > Dasatinib in preclinical studies has been > associated with long Q-T > intervals and that is why they do EKGs on the > trial. Dasatinib and > AMN107 are more associated with heart issues. > > http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Imatinib.htm > > www.cancercare.on.ca/pdfdrugs/Imatinib-Mesylate.pdf > > http://www.americanheart.org/presenter.jhtml?identifier=4637 > > I am giving the abstract below. It is only 2 > patients who had problems > so I would say heart problems with Gleevec is > rare. Still, you can > show the abstract to the cardio. > > Hope everything will be well, Dianne. > > Love, > Anjana > > Cancer Lett. 2005 Dec 30; [Epub ahead of print] > Related Articles, Links > > > > BNP as a marker of the heart failure in the > treatment of imatinib > mesylate. > > Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon > SH, Yim SV, Chung JH. > > Department of Medical Oncology, Korea Institute > of Radiological and > Medical Sciences, Seoul 130-706, South Korea. > > Since its introduction 6 years ago, imatinib > mesylate, a selective > tyrosine kinase inhibitor, has been a > phenomenon in treating chronic > myelogenous leukemia (CML) with remarkably > superior cytogenetic and > molecular response rates at all stages of CML > followed by longer > progression free survival. Despite its > extraordinarily high efficacy, > adverse effects of imatinib mesylate such as > edema, liver toxicity and > fluid retention syndromes have been reported. > Here we, for the first > time, report development of heart failure in > patients on imatinib > mesylate medication and the possibility of > brain natriuretic peptide > (BNP) as a potential diagnostic (or predicting) > marker for heart > failure. Since plasma BNP levels in the two > patients were exceptionally > high, we then explored the possibility of > genetic association of BNP > with the development of heart failure to find > no positive association. > > > > > __________________________________________________ Do You Yahoo!? Tired of spam? Yahoo! Mail has the best spam protection around http://mail.yahoo.com --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
